Caroline Palomeque
Stock Analyst at Maxim Group
(2.58)
# 2,222
Out of 4,944 analysts
9
Total ratings
55.56%
Success rate
16.24%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Caroline Palomeque
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| DARE Daré Bioscience | Downgrades: Hold | n/a | $2.11 | - | 2 | Aug 14, 2024 | |
| HRMY Harmony Biosciences Holdings | Initiates: Buy | $59 | $36.67 | +60.89% | 1 | Sep 7, 2023 | |
| KRYS Krystal Biotech | Initiates: Buy | $154 | $149.36 | +3.11% | 1 | Sep 7, 2023 | |
| HALO Halozyme Therapeutics | Reinstates: Buy | $58 | $65.13 | -10.95% | 1 | Mar 27, 2023 | |
| ASND Ascendis Pharma | Assumes: Buy | $166 | $191.15 | -13.16% | 1 | Aug 30, 2022 | |
| DNLI Denali Therapeutics | Initiates: Buy | $39 | $14.81 | +163.34% | 1 | Jun 23, 2022 | |
| RGNX REGENXBIO | Initiates: Buy | $61 | $8.93 | +583.09% | 1 | Jun 23, 2022 | |
| AVXL Anavex Life Sciences | Initiates: Buy | $40 | $10.56 | +278.79% | 1 | Jun 23, 2022 |
Daré Bioscience
Aug 14, 2024
Downgrades: Hold
Price Target: n/a
Current: $2.11
Upside: -
Harmony Biosciences Holdings
Sep 7, 2023
Initiates: Buy
Price Target: $59
Current: $36.67
Upside: +60.89%
Krystal Biotech
Sep 7, 2023
Initiates: Buy
Price Target: $154
Current: $149.36
Upside: +3.11%
Halozyme Therapeutics
Mar 27, 2023
Reinstates: Buy
Price Target: $58
Current: $65.13
Upside: -10.95%
Ascendis Pharma
Aug 30, 2022
Assumes: Buy
Price Target: $166
Current: $191.15
Upside: -13.16%
Denali Therapeutics
Jun 23, 2022
Initiates: Buy
Price Target: $39
Current: $14.81
Upside: +163.34%
REGENXBIO
Jun 23, 2022
Initiates: Buy
Price Target: $61
Current: $8.93
Upside: +583.09%
Anavex Life Sciences
Jun 23, 2022
Initiates: Buy
Price Target: $40
Current: $10.56
Upside: +278.79%